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Abstract: Novel treatment modalities, including gene therapy, are 
needed for patients with advanced melanoma. We evaluated 
whether the gef gene, a suicide gene from Escherichia coli, had a 
significant cytotoxic impact on melanoma in vivo. First, we used a 
non-viral gene delivery approach (pcDNA3.1/ge/) to study the 
inhibition of melanoma cells (B16-F10) proliferation in vitro. 
Secondly, we used direct intra-tumoral injection of pcDNA3.1/ge/ 
complexed with jetPEI to deliver gef cDNA to rapidly growing 
murine melanomas. We demonstrated that gef gene not only has 
an antiproliferative effect on B16-F10 cells in vitro, but also 
Introduction 
Melanoma represents only 4% of all skin cancers, but nearly 
80% of skin cancer deaths, predominantly because of meta-
static spread (1). Apart from surgery, treatment options for 
melanoma, particularly metastatic melanoma, are relatively 
limited. As melanoma is a highly therapy-refractory tumor, 
it demands effective therapies combinations (2). Suicide gene 
therapy has been proposed as a strategy for the treatment of 
intractable cancers and has been assayed in some clinical tri-
als by itself or in combination with other therapies (tumor 
irradiation or chemotherapy). In melanoma, strategies to 
facilitate apoptosis by gene therapy may be an alternative or 
complementary strategy for its treatment (3) as it has been 
demonstrated that apoptosis deficiency is a critical factor for 
therapy resistance in this tumor (4). 
Classical cancer suicide gene therapy employs genes encod-
ing enzymes that convert non-toxic prodrugs into cytotoxic 
compounds (5). However, these prodrug systems have been 
assayed in melanoma both in vitro and in vivo with limited 
induces an important decrease in melanoma tumor volume 
(77.7% in 8 days) in vivo. Interestingly, after gef gene treatment, 
melanoma showed apoptosis activation associated with the 
mitochondrial pathway, suggesting that the induction of this 
death mechanism may be an effective strategy for its treatment. 
Our in vivo results indicate that gef gene might become a suitable 
therapeutic strategy for patients with advanced melanoma. 
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results (6,7). As an attractive alternative to this strategy, ther-
apeutic genes that directly encode cytotoxic proteins could 
be used. In contrast to classical suicide genes that act by dis-
rupting DNA synthesis (targeting only rapidly dividing cells) 
these new toxins may act killing both quiescent and rapidly 
dividing tumor cells and may be effective for aggressively 
growing tumors as well as for those that grow more slowly. 
Many genes encoding cytotoxic products have been evalu-
ated as gene therapy approaches (8,9). The most recent expe-
riences with genes expressing toxins from bacteria (10), from 
plants (11) or from bacteriophage (12) showed a high cyto-
toxic impact on tumoral cells derived from different tissues. 
In this context, our group has developed last year a 
direct cancer gene therapy system based in the suicide gene 
named gef. The gef gene, member of a gene family with 
homologous cell-killing functions, encodes a membrane 
protein of 50 amino acids which is anchored in the cyto-
plasmic membrane by the N-terminal portion, whereas the 
C-terminal part is located in the periplasm (13). Although 
activation of this protein induces arrest of respiration and 
death in bacterial cells the mechanism of action in tumoral 
cells is unclear. We have previously demonstrated that gef 
protein is able to induce changes in proliferation rate and 
differentiation degree of tumoral cells without having to 
use prodrugs (14,15). However, its possible in vivo applica-
tion could not be demonstrated yet. 
In this study, we have evaluated for the first time the 
potential use of the gef gene for the treatment of melanoma 
tumors in vivo. Moreover, based on the knowledge that the 
gef gene encodes a cytotoxic protein that binds to cell mem-
branes, we analysed gef s mechanism of action. We used the 
B16-F10 murine melanoma model because of its highly inva-
sive and metastatic nature and the cationic lipids jetPEI to 
deliver gef cDNA to rapidly growing murine melanomas. 
Results obtained suggest that treatment with the gef gene sig-
nificantly decreases tumor growth, inducing apoptosis in mel-
anoma tumor cells by means of the mitochondrial pathway. 
Methods 
Cells and reagents 
The B16-F10 murine melanoma cell line (CRL6475) was 
obtained from American Type Culture Collection and was 
grown in Dulbecco's modified eagle's medium (Sigma, 
St Louis, MO, USA), supplemented with 10% heat-inacti-
vated foetal bovine serum, 2 mM L-glutamine, 40 mg/1 
gentamicin and 500 mg/1 ampicillin (Antibióticos S.A, 
Madrid, Spain). Cells were maintained in monolayer cul-
ture at 37°C in an atmosphere containing 5% C02 . 
gef transfection in B16-F10 cells 
The gef gene was amplified using specific primers (sense 
5'-ATGAAGCAGCATAAGGCGATG-3' and antisense 5'-
TTACTCGGATTCGTAAGCCGTC-3') under the following 
conditions: 94°C for 1 min, 35 cycles at 94°C for 1 min, 
53°C for 30 s and 72°C for 30 s and 72°C for 10 min and 
was subcloned into the pcDNA3.1-TOPO vector (Invitro-
gen, Barcelona, Spain) following the manufacturers' 
instructions. The resulting plasmid pcDNA3.1/ge/ was 
transformed into the subcloning efficiency DH5 alpha 
chemically competent Escherichia coli (Invitrogen). The cor-
rect DNA sequence was confirmed by sequence analysis 
using the T7 primer. One day before transfection, confluent 
cells were seeded into six-well plates (2 X 105 cells/well). 
Briefly, a transfection mixture was prepared by adding 
94 ¡A of the serum-free medium and 6 /A FuGENE-6 
reagent (Roche Diagnostic, Barcelona, Spain). After 5 min 
of incubation at room temperature, 2 /ig of plasmid DNA 
(pcDNA3.1/£e/) were added (ratio 1:3). B16-F10 cells, 
yielding approximately 70% confluence, were transfected 
with gef gene-containing pcDNA3.1 vector. Cells were culti-
vated for 8 h at 37°C, and the medium containing transfec-
tion mixture was then replaced with the growth medium. 
A pcDNA3.1 plasmid in which the gef gene was absent was 
used as a negative control. The pcDNA3.1/green fluores-
cent protein (GFP) (provided by Dr. G. Ortiz) was used to 
optimize transfections conditions. 
Proliferation assays 
Parental and transfected cells growing in well plates were 
trypsinized after 24, 48, 72 and 96 h and collected. Cells 
were fixed and stained with 0.4% sulphorhodamine B/1% 
acetic acid. Cells previously washed with 0.1% acetic acid 
were left in 10 mM Trizma for 15 min at room tempera-
ture. Optical density was then determined using a Titertek 
multiscan (Flow, Irvine, CA, USA) colorimeter at 492 nm. 
Linearity of the SRB assay with cell number was tested for 
each B16-F10 cell stock before each cell growth experiment. 
B16-F10 cells transfected with empty vector were used in 
the proliferation assay as controls. 
In vitro and in vivo expression of gef gene 
Upregulation of mRNA expression of gef cDNA was deter-
mined by RT-PCR. RNA was extracted from transfected and 
parental cells with the RNeasy Mini kit (Qiagen, Valencia, 
CA, USA). RNA from tumor was obtained with the RNeasy 
Fibrous Tissue Mini Kit (Qiagen). cDNA was generated by 
means of the Promega reverse transcription system using 
total cellular RNA (1 /ig). PCR amplification of gef gene 
took place under the above-described conditions. RNA 
integrity was assessed by amplification of /i-actin mRNA. 
Images were scanned and analysed using a Bio-Rad docu-
mentation system (Quantity One Analysis Software, Bio-Rad 
Laboratories, Barcelona, Spain). Relative gef mRNA expres-
sion was calculated as the ratio of gef to /i-actin. 
Annexin V and propidium iodide staining 
Parental and transfected cells were washed twice with 
phosphate-buffered saline (PBS) and incubated in binding 
buffer containing annexin V-FITC (25 /ig/nA) and propidi-
um iodide (25 /ig/mY) in the dark for 15 min at room 
temperature (Annexin V-FITC Apoptosis Detection Kit I; 
BD Pharmingen, San Diego, CA, USA). Then, binding buf-
fer (500 /A) was added and cells were immediately pro-
cessed with a FACScan flow cytometer. Microscopy analysis 
was carried out by Technical Services from the Granada 
University in a Leica DMI6000 (Heidelberg, Germany) con-
focal microscope with laser Argon/Krypton. 
Assay for cytoplasmic mono- and 
oligonucleosomes 
The Cell Death Detection ELISA Kit (Boehringer, Mann-
heim, Germany) was used for assessing apoptosis in trans-
fected cells following the manufacturer's protocol. Parental 
and transfected cells (2 X 104) were lysed and the cell 
lysates were overlaid and incubated in microtitre plate 
modules coated with antihistone antibody. Samples were 
then incubated with anti-DNA peroxidase followed by colour 
development with ABTS (2,2'-Azino-bis(3-Ethylbenzthiazo-
line-6-Sulfonic Acid)) substrate. Samples absorbance was 
determined with Titertek multiscan at 405 nm. 
Measurement of mitochondrial membrane 
potential 
Parental and transfected cells were washed twice with cold 
PBS and incubated with 40 nM DiOC6(3) for 15 min at 
37°C. Then, cells were washed with ice-cold PBS and resus-
pended in 500 ml of PBS. Fluorescence intensities of 
DiOC6(3) were analysed on a FACScan (Becton Dickinson, 
San Jose, CA, USA) flow cytometer with excitation and 
emission settings of 484 and 500 nm, respectively. 
Caspase activity assay 
Caspase-9 and -8 activities were measured using caspase col-
orimetric assay kits (R&D Systems, Minneapolis, MN, USA). 
Briefly, parental and transfected cells were washed twice with 
cold PBS and resuspended in 50 /A of cold lysis buffer, incu-
bated for 10 min and centrifuged for 1 min at 10 000 g to 
precipitate cellular debris. Assay was performed in triplicate 
on a 96-well plate following the manufacturers' protocol. 
Results are expressed as the fold increase in pcDNA3.1/ge/ 
treated cells over that of control cells. Etoposide (Sigma, St. 
Louis, MO, USA) (50 /miol/1) was used as positive control 
of caspase activities in B16-F10 cells. 
Tumor induction and measurement 
For in vivo study, female C57BL/6 mice (Scientific Instru-
mentation Centre, Granada University, Granada, Spain) were 
used. All mice (weighing 25-30 g) were maintained in a lam-
inar air-flow cabinet at a room kept at 37°C temperature and 
40-70% humidity with a 12-h light/dark cycle under specific 
pathogen-free conditions. All studies on animal models were 
approved by the Ethical Committee of the Medical School of 
Granada University and performed according to its guide-
lines. Tumors were induced by subcutaneous injection of 
5 X 105 B16-F10 cells into the left flanks of C57BL/6 mice. 
Tumors were allowed to grow to the appropriate size 
(75 mm3) before treatment (ideal minimal size for intra-
tumoral injection). After reaching this volume (treatment 
day 0), tumors were measured at periodic intervals following 
treatment using a digital caliper by measuring the longest 
diameter (a) and the next longest diameter (b) perpendicular 
to (a). Using these measurements the tumor volume was cal-
culated by the formula V = ab2 X K/6. 
Intra-tumoral plasmid treatment 
In vivo JetPEI (Polyplus-transfection Inc., New York, NY, 
USA) was used as a transfection enhancer reagent. PEI/DNA 
complexes with a ratio of 1:6 were prepared in a solution of 
10% w/v glucose. This was carried out in a two-step proce-
dure for the preparation of a standard quantity of 20 /ig 
of PEI/DNA complex, according to the manufacturer's 
instructions. Tumors were then treated intra-tumorally with 
pcDNA3.1/ge/ plasmid. The pcDNA3.1 LacZ plasmid was 
used to normalize transfection efficiency. Moreover, control 
groups (without treatment and treated with empty vector) 
were included. Treatments were administered during 
14 days. Comparative study between treated and non-treated 
groups was realized during the first 8 days because of the 
high rate of mortality in control group. 
Histological analysis 
Tumors were fixed in 4% paraformaldehyde in PBS, embed-
ded in paraffin and cut into 3-5 /mi sections. Cells were im-
munofiuorescently labelled with primary antitubulin mouse 
monoclonal antibody (1:500) (Sigma) followed by Texas Red 
dye-conjugated affinitPure Goat Anti-Mouse IgG + IgM 
(1:500) (Jackson ImmnoResearch Laboratories, West Grove, 
PA, USA). The presence of apoptotic cells within the tumor 
sections was evaluated by the TUNEL technique using the 
In Situ Cell Death Detection Kit Fluorescein (Roche, Mann-
heim, Germany) according to manufacturers' recommenda-
tions. Cell nuclei were counterstained with DAPI. Per cent 
apoptosis (apoptotic index) was determined by counting the 
number of apoptotic cells and dividing by the total number 
of cells in the field (5 high power fields/slide). Immunohisto-
chemical analyses of caspases were realized using antiactive 
forms of caspase-9 (1:50) (Cell Signaling Technology, Inc, 
Danvers, MA, USA) and caspase-8 (1:100) (Imgenex, San 
Diego, CA, USA). FITC-conjugated antirabbit secondary 
antibody at room temperature for 1 h was used for the detec-
tion. Cell nuclei of cultures were counterstained with DAPI. 
Fluorescence images were captured using an Olympus DP 11 
microscope with a Nikon Eclipse Ti (Nikon Instruments 
Inc., New York, NY, USA) digital imaging system. 
Transmission electron microscopy 
Melanoma tumors grown in mice were collected, cut up 
into small pieces and immediately fixed with 2.5% glutar-
aldehyde in 0.1 M cacodylate buffer (pH 7.2) at room tem-
perature for 1 h. After postfixation with 1% Os04 in 
cacodylate buffer (room temperature, 2 h), sections were 
dehydrated through graded ethanol concentrations with a 
final propylene oxide dehydration. Samples were then 
embedded in Epon 812 resin. Ultrathin sections, were 
stained with uranyl acetate and lead citrate and examined in 
a Hitachi H7000 transmission electron microscope (TEM, 
Hitachi High-Technologies Corporation, Tokyo, Japan). 
Statistical analysis 
SPSS 14 software (SPSS Inc., Chicago, IL, USA) was used 
for all statistical analyses. Results were compared by using 
the Student's f-test. All data are expressed as mean + SD. 
Differences were considered statistically significant at a 
P-value of <0.05. 
Results 
Expression of gef gene and inhibition of cell 
growth in B16-F10 cells in culture 
In vitro evaluation of gef gene expression was performed by 
RT-PCR. As shown in Fig. la, an amplification fragment of 
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Figure 1. gef gene expression and growth rate inhibition in B16-F10 
cells, (a) RT-PCR showing gef gene expression in B16-F10 transfected 
cells at different time periods. The integrity of the RNA was 
demonstrated using /i-actin primers. N, negative control (B16-F10 non-
transfected cells); M, molecular weight; P, positive control 
(pcDNA3.1/ge/). (b) Representative photomicrograph (phase contrast 
and fluorescent images) of B16-F10 cells transfected with 
pcDNA3.1/GFP to optimize transfections conditions, (c) Growth of B16-
F10 cells expressing gef was detected by sulphorhodamine B assay. 
Cells transfected with pcDNA3.1/gef showed a clearly decreased 
growth rate compared to the control cells and cells transfected with 
pcDNA3.1 empty vector (P < 0.0B). Data represent the mean ± SD of 
four independent experiments. 
153 bp was found in B16-F10 cells transfected with 
pcDNA3.1/ge/ for different time periods, indicating the 
effectiveness and ability of the construction in order to be 
used in the subsequent experiment. To demonstrate the 
integrity of the RNA preparations, PCR was performed 
using /i-actin primers. Analysis of the bands, normalized by 
comparison with the /i-actin signal, showed a progressive 
increase of gef expression; this was 3.9- and 4.5-fold higher 
at 48 and 72 h vs B16-F10 cells at 24 h and was maximal 
at 96 h after transfection (sixfold higher vs B16-F10 cells at 
24 h). Previously, cell transfection was optimized by 
pcDNA3.1/GFP (Fig. lb). As shown in Fig. lc, the B16-F10 
cells transfected with pcDNA3.1/ge/ showed a significant 
and time-dependent decrease in growth. Twenty-four hours 
after transfection a 28% decrease in growth rate versus 
control cultures was observed. The decrease in proliferation 
was 45.5% at 48 h. The main decrease in proliferation rate 
occurred at 72 h and 96 h, when similar ratios of growth 
decrease were observed (64.6% and 69.7%, respectively). In 
contrast, the growth of B16-F10 cells transfected with the 
empty vector (control group) was similar to that of the 
parental cells. 
Expression of gef gene-induced apoptosis in 
B16-F10 cells 
Apoptotic rates of B16-F10 cells untreated or transfected 
with empty vector revealed no significant difference. Only 
8.7% of the pcDNA3.1/ge/ transfected cells showed apopto-
sis after 24 h. However, at 48 and 72 h a significant 
increase was found (19% and 34%, respectively) (Fig. 2a). 
At 96 h apoptosis was similar to that found at 72 h (data 
not shown). These results indicated the ability of gef gene 
to stimulate apoptosis in B16-F10 melanoma cells after in 
vitro transfection. The induction of apoptosis by gef gene 
was also evident by confocal laser-scanning microscopy 
(Fig. 2b). Furthermore, to confirm whether the growth 
inhibitory effects of gef gene are related to the induction of 
apoptosis, we used an ELISA-based assay. Amounts of cyto-
plasmic oligonucleosomes (an indicator of apoptosis) 
increased between 24 and 96 h after gef transfection as 
compared with untreated cells. As shown in Fig. 2c, the 
strongest enrichment factor was obtained at 72 and 96 h 
(3.6 and 5.4, respectively). These results provide convincing 
data that up-regulation of gef induces apoptosis in B16-F10 
cancer cells. 
Gef gene therapy-induced modulation of 
mitochondrial membrane potential and 
caspase-9 activation 
To determine if induced apoptosis by gef gene in B16-F10 
cells is mediated via the mitochondrial pathway, mito-
chondrial membrane integrity was measured by DiOC6(3) 
dye staining. As shown in Fig. 3a, a significant decrease in 
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Figure 2. Analysis of apoptosis induction by gef gene in B16-F10 cells, 
(a) Fluorescence-activated cell sorting. Cells were stained with annexin 
V and propidium iodide (PI) to evaluate apoptotic cell death, as 
described in Methods. These data are representative results from four 
separate experiments, (b) Annexin V-FITC staining and confocal 
microscopy. The annexin V-FITC fluorescence localized at the periphery 
of the cells consequent to the translocation of phosphatidylserine (PS) 
residues from the inner leaflet of the plasma membrane to the outer 
leaflet. B16-F10 cells 48 h after transfection (a). Cell nuclei were 
counterstained with PI before examination under a confocal laser-
scanning microscope. A stronger binding was observed when the study 
was carried out 96 h after gef transfection (b). The experiment was 
performed three times with identical results. Magnification: (a) 20x; (b) 
40x. (c) ELISA apoptosis assay of cytoplasmic nucleosomes. The specific 
enrichment of mono- and oligonucleosomes released into the 
cytoplasm was calculated using the formula: mean of absorbance of 
transfected cells/mean of absorbance of control cells = enrichment 
factor (EF). The EF was calculated relative to the control value (=1) of 
untreated cells. *P < 0.05; * * P < 0.01 compared to control cells. 
membrane potential was detected in transfected cells at 24, 
48 and 72 h compared with parental cells (control) indicat-
ing a mitochondrial membrane permeability increase after 
gef gene treatment. At 96 h membrane potential modula-
tion was similar to that found at 72 h (data not shown). 
Caspase-9 activity was induced after gef gene treatment in 
B16-F10 cells. Although its activity was modulated at dif-
ferent times, the largest increase was observed at 72 and 
96 h (three- and 4.1-fold; respectively). The caspase-8 
activity remained unchanged (Fig. 3b). These data support 
the hypothesis that gef gene-induced apoptosis through the 
mitochondrial-mediated pathway. 
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Figure 3. Mitochondrial membrane potential and caspase activity. 
(a) Reduction of mitochondrial transmembrane potential {A\¡/m) in B16-
F10 cells (black) after 24 h (red), 48 h (grey) and 72 h (green) of gef 
transfection. DiOC6(3) was added to the culture medium during the 
last 15 min of treatment at a final concentration of 40 nis/i. The 
fluorescence intensity of DiOC6(3) was analysed by flow cytometry. 
Data shown are representative of three independent experiments. 
(b) Caspase-9 and -8 activities were determined (as described in 
Methods) in pcDNA 3.1 /gef transfected B16-F10 cells at indicated time 
points in comparison with parental cells (percentage values). Etoposide 
treatment (6 h) was used to demonstrate caspase 8 and caspase 9 
activities in B16-F10 cells. Experiments were performed four times with 
identical results. *P < 0.05; * * P < 0.01 compared to control cells. 
Gef gene effects on melanoma growth in vivo 
The potential of gef gene to promote tumor cell killing in 
vivo was evaluated by direct injection of the plasmid com-
plexed with jetPEI in B16-F10 subcutaneous mice tumors. 
Figure 4 shows that gef gene was able to inhibit tumor 
growth. During the first 2 days following treatment, tumor 
volume decreased by 40.4% in the gef gene treated group, 
as compared with the control group. On post-treatment 
days 4 and 6, the observed reduction was 45.2% and 54.3% 
respectively. Following a similar trend, a 77.7% volume 
reduction was observed on day 8. After this time, the con-
trol group showed a high mortality rate (Fig. 4). Mice trea-
ted with gef gene showed no evidence of systemic toxicity 
(i.e. animal death, loss of body weight, other tissue damage 
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Figure 4. Effect of direct ¡ntra-tumoral injection of the gef gene on 
the growth of subcutaneous tumor induced by B16-F10 tumors cells in 
mouse, (a) Tumor volume variation after gef gene treatment. Time of 
njection is indicated through arrows; treatment began (day 0) when 
tumors had reached a volume of 75 mm3. The plot shows a significant 
tumor volume reduction in the treated group (n = 14) as compared 
with the control groups, transfected with empty vector (n = 7) and 
without treatment (n = 7). (b) Representative gross appearance of 
tumors excised from mice sacrificed during treatment at 2 (a'), 4 (b') 6 
(c') and 8 (d') days and tumors obtained from mice without treatment 
at the same time intervals (a, b, c and d, respectively), (c) Determination 
of gef gene expression in tumor mice after 2 and 8 days of 
pcDNA3.1/gef treatment. The integrity of the RNA tissue used was 
determined using ¡i-actin primers. M, molecular weight; P, positive 
control (pcDNA3.1/gef); N, negative control (mouse tumors without 
treatment). 
or changes in behaviour or aspect). After empty vector 
injection with jetPEI, no tumor growth modifications were 
observed (Fig. 4a,b). RT-PCR was performed to ensure gef 
gene expression in all treated tumors. Figure 4c shows a 
comparison of gef gene expression in melanoma tissue 
between days 2 and 8 after the treatment. 
gef gene-induced apoptosis in melanoma cells 
in vivo 
To determine the gef expression efficiency to induce apop-
tosis in vivo we analysed established subcutaneous B16-F10 
tumors with a TUNEL reaction mixture. As showed in 
Fig. 5a, the number of apoptotic cells (green) was signifi-
cantly higher in tumors treated with pcDNA3.1/ge/in com-
parison with the tissue control. Analysis of the melanoma 
sections showed a progressive increase of per cent apoptosis 
which was maximal at 8 days after treatment (Fig. 5b). To 
examine possible caspase-9 or -8-activation by gef gene 
treatment we used immunohistochemistry. Weak or absent 
expression of caspase-8 protein was detected in tissue sam-
ples (data not shown). However, all samples of melanoma 
tissue treated with pcDNA3.1/ge/at different times showed 
a clear caspase-9 activation, with the strongest staining 
observed from the 4th day of treatment until the end of 
the experiment. Caspase-9 expression was not seen in any 
of the controls or in melanoma tissue treated with the 
empty vector (Fig. 5c). 
Transmission electron microscopy 
To further investigate the nature of gef gene-mediated cyto-
toxicity, B16-F10 mouse melanoma-induced tumors treated 
with gef gene in vivo were analysed by TEM. The control 
tissue showed giant malignant cells with an intact cell 
membrane and single- or multiple-nuclei cells. The first 
identifiable morphological change after treatment was the 
pronounced swelling in the mitochondria seen within 
2 days of treatment. Mitochondria in control cells and cells 
treated with vehicle alone remained unaffected. Forty-eight 
hours later, apoptosis ultrastructural characteristics, such as 
chromatin condensation, crescent formation and margin-
ation were seen by electron microscopy in the treated mela-
noma, but not in the control group. Similar pictures were 
observed 6 and 8 days after treatment (Fig. 6). 
Discussion 
New treatment strategies for malignant melanoma are 
urgently needed because conventional approaches like che-
motherapy and radiation have little impact on patient sur-
vival in the advanced stages of the disease. As a promising 
alternative, gene therapeutic strategies based on suicide 
gene expression in tumor cells have been developed. In this 
study, we have demonstrated the in vivo potential use of 
the gef cDNA as a suicide gene in a new melanoma gene 
therapy approach. 
To date, classical suicide gene therapy systems have not 
guaranteed the successful treatment of melanoma and have 
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Figure 5. Histological evaluation of apoptosis and caspase activity of 
melanoma cells in vivo, (a) Representative photographs of tumor 
sections showing TUNEL-positive cells (green). Sections were 
counterstained with DAPI (blue) and anti-tubulin (red). Apoptotic cells 
ncreased in tumors treated with pcDNA 3.1/gef at 2 (data not shown), 
4, 6 and 8 days compared to untreated tumors (control) (x20). (b) Per 
cent apoptosis in each group. Values were expressed as mean ± SD. 
Level of significance compared to control cells: *P< O.OB; * * p < 0.01. 
(c) Caspase expression in melanoma tumor was detected using 
immunofluorescence staining. Microscopic analysis showed that 
melanoma tissue after treatment with pcDNA3.1/gef was strongly 
caspase-9-positive. Untreated tumors (a) and melanoma tumor after 4 
(b) (40x) and 6 (c) (60x) days of treatment. Cell nuclei counterstained 
with DAPI showed that some cells displayed apoptotic morphology and 
nuclear segmentation (arrows) (d, 60x). All data were obtained from 
the study of at least three tumors. 
induced only a partially positive response (16,17). One of 
the main limitations of these indirect action systems is the 
need to use prodrugs (18).The use of genes encoding toxins 
avoids the administration of a prodrug, eliminating its 
side-effects, its bioavailability limitations and the consecu-
tive applications of vector and prodrug. Moreover, these 
genes can be directly expressed in the cytosol of the target 
cells, thus overcoming the problems (cytotoxicity, internali-
zation efficiency and resistance acquired by cancer cells) 
originated by their use as components of immunotoxins or 
recombinant chimeras (19). In melanomas, viral genes 
encoding toxins such as viral protein R and some plant 
Figure 6. Transmission electron microscopy of melanoma tumors 
without treatment showed typical tumor cells with polygonal shape, 
large nucleus, light cytoplasmic complexion containing well preserved 
organelles (a) including mitochondrias (A insert) (1100x) and a large 
amount melanosomes (B insert) including premelanosomes (arrows) (b) 
(x4000). Representative photomicrograph of melanoma treated with 
pcDNA3.1/gef (6 days) showing ultrastructural characteristics of 
apoptosis such as chromatin condensation, crescent formation and 
margination (c) (x6300). Note, the nucleus near of the swollen 
mitochondrias (white arrows) with disrupted cristae (black arrows) 
(d) (12000x). Data were obtained from the study of at least three 
tumors. 
genes such as saporin (SAP) have been applied with a sig-
nificant result to induce tumoral cell death (20,21). Our 
previous results in vitro showed that gef is effective in mela-
noma MS-36TG cells, modulating their proliferation capac-
ity, differentiation degree and tumor malignancy (22). In 
the present study, we have demonstrated that the transfec-
tion of the pcDNA 31/gef not only inhibits in vitro mela-
noma proliferation but also it is highly toxic for tumors in 
vivo. The gef gene treatment induced a significant decrease 
in tumor growth (77.7% relative volume reduction after 
8 days of treatment), an effect that was clearly improved 
upon repeated administrations. Experimental treatment 
with HSV-tk/GCV (23) or more recently with the SAP 
gene (21) in the same tumor type, induced a 40-50% and 
67% relative volume reduction, respectively. McCray et al. 
(20), who used the Vpr gene integrated in the pcDNA3.1 
(100 //g) vector in melanoma tumor from B16-F10 culture 
cells, described an 86% of tumor volume reduction which 
required 25 days of treatment. Therefore, the main advan-
tage of the gef gene is not only its efficacy in melanoma 
cells but also the shorter latency for effective antitumoral 
action. 
Although we have demonstrated the cytotoxic effect of 
gef gene in cancer cells, the specific mechanism of action 
has remained unclear so far. In prokaryotic cells, the gef 
gene diminishes the membrane potential, leads to mem-
brane leakiness and also induces morphological changes 
(24). Eukaryotic cells fundamentally differ from prokary-
otic cells in terms of their cellular structure, organization, 
metabolism and membrane composition. Nevertheless, as 
the eukaryotic endomembrane system arose in an ancestral 
prokaryotic lineage (25) gef gene might act in cell orga-
nelle membranes. Recently, it was demonstrated that 
breast cancer cells growth was inhibited by bacteriophage 
2-holin, a protein that can permeabilize the bacterial 
membrane (12). Our results showed that 48 h after induc-
tion B16-F10 cells become multinucleated, in some cases 
extensively vacuolated and finally detached from the cul-
ture dish surface. Experiments with annexin, confocal 
laser-scanning microscopy and nucleosomes clearly showed 
that the gef gene is able to induce apoptosis in a time-
dependent manner. These results are similar to those 
obtained with the SAP gene which also induces pro-
grammed cell death and direct DNA fragmentation in 
B16-F10 cells (21). Interestingly, the pronounced clinical 
chemoresistance of melanoma is strongly suggestive of an 
inactivation of apoptotic programmes. Defects in proapop-
totic signalling pathways and enhancement of antiapop-
totic pathways may synergistically contribute to this 
apoptosis deficiency (26). Immunohistochemical analysis 
by TUNEL assay revealed that pcDNA3.1/ge/ treatment 
significantly increased apoptosis in established subcutane-
ous B16-F10 tumors in vivo. The incidence of apoptosis in 
the tumor almost corresponded to the effect of tumor 
growth inhibition, suggesting that our experimental treat-
ment resulted in tumor regression by significant augmen-
tation of apoptosis. 
Apoptosis may occur via death-receptor dependent 
(extrinsic) or mitochondrial (intrinsic) pathways. The 
extrinsic pathway is triggered by the activation of death 
receptors, such as Fas and TRAIL receptors (DR4, DR5) 
activating initiator caspase-8, which then cleaves execu-
tioner caspase-3. The mitochondrial pathway of cell death 
is mediated by Bcl-2 family proteins, which disrupt the 
mitochondria membrane potential and result in release of 
apoptogenic factors, such as cytochrome c, from the mito-
chondria into cytosol; in turn, these factors would form an 
apoptosome with apoptosis activating factor 1 and caspase-9 
(27). Treatments modulating apoptosis phenomenon, for 
example with bcl-2-targeted antisense, are a promising new 
strategy in melanoma (28). Assays with drugs such as 
hydroquinone or thiobenzanilides in this tumor type have 
demonstrated an action mechanism related to caspase-9 
activation (29,30). This tumoral cellular injury mediated by 
caspases may also be induced by suicide genes and it may 
be relevant in relation to their application in tumors. In 
fact, CD/5FC system induces apoptosis in human malig-
nant glioma cells by the activation of caspases-3 and -9 but 
not caspase-8 (31) while a certain modification, the bifunc-
tional E. coli cytosine deaminase and uracil phosphoribosyl-
transferasefusion, is able to induce caspase-3 activation 
only (32). HSVf/c/GCV activates caspase-3, -8 and -9 in rat 
bladder carcinomas (33) and a variant, the thymidylate 
kinase, induces apoptosis in Jurkat cells by activation of 
caspase-3 only (34). Our studies in B16-F10 cells expressing 
gef showed alteration of the mitochondrial membrane 
integrity suggesting that apoptosis is mediated by the mito-
chondrial pathway. This hypothesis is supported by the 
caspase-9 activity increase in B16-F10 transfected cells. 
Moreover, the mitochondrial transmembrane potential is 
altered in most of the cellular population, supporting the 
hypothesis on the possible effect of gef once it is released 
from the apoptotic cells. The mitochondrial-mediated 
apoptotic pathway is strongly supported by our ultrastruc-
tural findings in the induced B16-F10 tumors in mice 
which showed dilated mitochondria with disrupted cristae. 
Moreover, the in vivo assay shows that caspase-9 activity 
increases significantly after gef gene treatment, supporting 
the participation of a mitochondrial-mediated apoptotic 
pathway in our gene therapy system. However, we can not 
exclude the possible participation of other apoptosis-medi-
ated molecule in treated B16-F10-induced tumors such as 
endonuclease G, Smac/DIABLO and HtrA2 (35). Further 
studies are required to elucidate the exact mechanisms 
involved. 
We have reported the successful use of the gef gene as an 
anticancer gene therapy system, not only in melanoma cells 
in culture but in melanoma tumors in vivo. Our in vivo 
experiments show that gef gene has a rapid and efficient 
activity in relation to tumor volume decrease. However, gef 
gene binds to the mitochondrial membrane and its activity 
is not tumor-specific. Therefore, it will be necessary to cre-
ate this specificity as in most of the toxic genes used in 
gene therapy (8-12). We have injected intra-tumorally the 
pcDNA3.1/gef plasmid to observe its activity in melanoma 
cells. Adenoviral vectors modified by attaching tumor-
specific promoters should be used to assay metastatic 
melanoma treatment. Currently, we are using specific 
enhancer/promoter genes (such as tyrosinase) (36), new 
vectors (such as ReCon) (37) and combined therapy with 
cytotoxic drugs (38) to improve the tumoral response 
against gef gene. Moreover, it will be necessary to demon-
strate the apoptosis induction in human melanoma by the 
extopic gef gene expression. In summary, our results sug-
gest that gef is a suicide gene candidate for oncologic in 
vivo applications and that it may contribute to eradicate 
tumor mass in combination with surgery or classic radio-
or chemotherapy. 
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